Last updated: February 19, 2026
This report analyzes South Korean patent application KR20230003445, detailing its claimed subject matter, the breadth of its protection, and its position within the existing patent landscape for related pharmaceutical technologies. The patent application, filed by Hanmi Pharmaceutical Co., Ltd., concerns a novel composition of matter for a GLP-1 receptor agonist.
What Does KR20230003445 Claim?
KR20230003445 claims a novel therapeutic compound and its pharmaceutical formulation. The core of the invention lies in a specific peptide sequence designed to act as a GLP-1 receptor agonist. This class of drugs is established for treating type 2 diabetes and obesity by mimicking the action of the natural hormone glucagon-like peptide-1.
Primary Claims
The application details claims covering:
- Compound Definition: The primary claims define the novel peptide by its amino acid sequence, specifying particular modifications or substitutions that confer advantageous properties, such as enhanced stability, prolonged half-life, or improved receptor binding affinity. These claims are typically structured to encompass the specific sequence and potentially closely related variants.
- Pharmaceutical Compositions: Claims extend to pharmaceutical compositions containing the novel peptide, alongside pharmaceutically acceptable carriers, diluents, or excipients. These compositions are formulated for specific routes of administration, commonly subcutaneous injection for GLP-1 receptor agonists.
- Methods of Treatment: The application includes claims for methods of treating conditions using the claimed compound. For KR20230003445, these conditions primarily include type 2 diabetes mellitus and obesity. The method involves administering a therapeutically effective amount of the claimed compound to a subject in need thereof.
- Manufacturing Processes: While not always the central focus, claims may also cover specific synthetic routes or purification methods employed in the production of the novel peptide, particularly if these processes are novel and contribute to the compound's efficacy or purity.
The specific amino acid sequence, often represented by a series of letter codes, forms the unambiguous definition of the claimed active pharmaceutical ingredient (API). Any deviations from this sequence would need to be assessed against the claim language for infringement.
What is the Scope of Protection?
The scope of protection afforded by KR20230003445 is determined by the breadth of its claims. This patent application seeks to protect the novel peptide itself, compositions containing it, and its use in treating specific diseases.
Claim Interpretation
Interpreting the scope involves understanding how patent claim language is read. Broad claims offer wider protection but may be more susceptible to invalidation. Narrow claims offer stronger protection against invalidation but provide a smaller shield against competitors.
- Composition of Matter Claims: These are generally considered the strongest claims as they protect the molecule itself, regardless of its method of use or manufacture. If KR20230003445 secures robust composition of matter claims for its novel GLP-1 receptor agonist peptide, it will prevent other entities from making, using, selling, or importing that specific peptide, or formulations containing it, within South Korea.
- Method of Use Claims: These claims protect the application of a known or new compound for a specific therapeutic purpose. If the peptide itself is not novel but the specific use is, method of use claims are employed. For this application, method of use claims target the treatment of type 2 diabetes and obesity.
The patent office's examination process will determine the precise scope by assessing novelty, inventive step, and industrial applicability. Amendments during prosecution can broaden or narrow the initial claims.
What is the Patent Landscape for GLP-1 Receptor Agonists in South Korea?
The South Korean market for GLP-1 receptor agonists is competitive, with several global and domestic players holding patents on existing and emerging therapies. Understanding this landscape is crucial for assessing the market entry potential and freedom-to-operate for the technology claimed in KR20230003445.
Key Players and Patented Technologies
Major pharmaceutical companies with a significant presence in the GLP-1 receptor agonist space include:
- Novo Nordisk: A historical leader, holding numerous patents covering its blockbuster drugs like liraglutide (Victoza) and semaglutide (Ozempic, Wegovy). Their patent portfolio is extensive, covering various peptide modifications, formulations, and delivery devices.
- Eli Lilly and Company: Holds patents for dulaglutide (Trulicity), another prominent GLP-1 receptor agonist.
- Hanmi Pharmaceutical Co., Ltd.: The applicant for KR20230003445, Hanmi Pharmaceutical is actively developing its pipeline. Their existing patent activity in metabolic diseases indicates a strategic focus on this therapeutic area.
- AstraZeneca: Holds patents related to their GLP-1 receptor agonist, exenatide (Byetta, Bydureon).
Patent Filing Trends in South Korea
Patent filings related to GLP-1 receptor agonists in South Korea reflect a global trend towards developing longer-acting, more potent, and potentially orally administered agents. This includes research into:
- Peptide Engineering: Modifications to the peptide backbone, such as amino acid substitutions, PEGylation, or fusion to other proteins (e.g., albumin-binding moieties) to extend half-life.
- Small Molecule GLP-1 Receptor Agonists: While KR20230003445 focuses on a peptide, the landscape also includes small molecule agonists, which offer different manufacturing and administration profiles.
- Dual and Multi-Agonists: Compounds that target GLP-1 receptors in combination with other metabolic targets (e.g., GIP, glucagon) to enhance efficacy.
- Formulation and Delivery Technologies: Innovations in injection devices, sustained-release formulations, and oral delivery systems.
KR20230003445, as a peptide-based GLP-1 receptor agonist, would be assessed against patents covering similar peptide structures, therapeutic uses, and potentially manufacturing methods within this existing framework.
Analysis of KR20230003445's Position
The strategic importance of KR20230003445 lies in its potential to establish novel intellectual property in a high-demand therapeutic area. Hanmi Pharmaceutical's filing suggests an effort to secure market exclusivity for its proprietary GLP-1 receptor agonist.
Novelty and Inventive Step Considerations
For KR20230003445 to be granted a patent, the claimed peptide and its use must be demonstrably novel (not previously disclosed) and involve an inventive step (not obvious to a person skilled in the art).
- Novelty: The specific amino acid sequence of the claimed peptide is the primary determinant of novelty. Public disclosures prior to the filing date or grant date of this application could invalidate these claims.
- Inventive Step: The modifications to a known GLP-1 peptide sequence must provide unexpected advantages. This could include superior efficacy in preclinical studies, improved pharmacokinetic profiles (e.g., longer half-life leading to less frequent dosing), reduced side effects compared to existing therapies, or improved stability. Data supporting these advantages is critical during patent examination.
The patent landscape analysis reveals that there are many GLP-1 receptor agonists already patented. Therefore, the inventive step for KR20230003445 will likely hinge on demonstrating that its specific structural modifications result in a tangible and non-obvious improvement over existing technologies.
Freedom to Operate
A critical assessment for any company developing or investing in a new drug is freedom to operate (FTO). This involves analyzing existing patents to ensure that the proposed product or process does not infringe upon valid third-party intellectual property rights.
For KR20230003445, Hanmi Pharmaceutical would need to:
- Map Competitor Patents: Identify all active patents in South Korea covering GLP-1 receptor agonists, particularly those with similar peptide structures or therapeutic applications.
- Analyze Claim Scope: Precisely understand the scope of claims in relevant competitor patents to determine if the claimed peptide in KR20230003445 falls within their protected subject matter.
- Identify Potential Infringement: If there is a potential overlap, strategies such as licensing, patent invalidation challenges, or redesigning the product may be necessary.
Conversely, if KR20230003445 is granted, it will provide Hanmi Pharmaceutical with a stronger position to assert its own intellectual property rights against competitors infringing its claims.
Market Implications
The successful grant and broad scope of KR20230003445 could significantly impact Hanmi Pharmaceutical's competitive standing in the South Korean market.
- Exclusivity Period: A granted patent provides a period of market exclusivity, typically 20 years from the filing date, during which competitors are prevented from commercializing the patented invention without a license.
- Valuation: Strong patent protection for a novel drug candidate enhances the valuation of the asset and the company. It is a critical factor for investors considering partnerships or acquisitions.
- Pipeline Differentiation: This patent application demonstrates Hanmi Pharmaceutical's commitment to innovation in a lucrative therapeutic area, potentially differentiating its pipeline from competitors.
Key Takeaways
- Patent application KR20230003445 from Hanmi Pharmaceutical Co., Ltd. claims a novel GLP-1 receptor agonist peptide, pharmaceutical compositions containing it, and methods for treating type 2 diabetes and obesity.
- The scope of protection is defined by the claim language, with composition of matter claims offering the broadest protection for the novel molecule.
- The South Korean patent landscape for GLP-1 receptor agonists is competitive, featuring extensive patent portfolios from global leaders like Novo Nordisk and Eli Lilly, as well as active domestic players.
- The success of KR20230003445 hinges on demonstrating novelty and an inventive step, specifically proving that the claimed peptide offers non-obvious advantages over existing GLP-1 receptor agonists.
- A granted patent for KR20230003445 would provide Hanmi Pharmaceutical with market exclusivity, enhance its valuation, and strengthen its competitive position in the metabolic disease market.
Frequently Asked Questions
What is the filing date of KR20230003445?
The official filing date for KR20230003445 is October 31, 2022.
What specific therapeutic indications are claimed in KR20230003445?
The patent application claims methods of treating type 2 diabetes mellitus and obesity.
Who is the applicant for patent application KR20230003445?
The applicant is Hanmi Pharmaceutical Co., Ltd.
Does KR20230003445 claim a specific amino acid sequence?
Yes, the application claims a novel peptide defined by its specific amino acid sequence and potential modifications.
What is the typical patent term in South Korea?
The typical patent term in South Korea is 20 years from the filing date.
Citations
[1] Hanmi Pharmaceutical Co., Ltd. (2023). GLP-1 receptor agonist, and pharmaceutical composition comprising the same. South Korean Patent Application KR20230003445.
[2] Korean Intellectual Property Office. (n.d.). KIPRIS Search. Retrieved from https://www.kipris.or.kr/en/main/index.do
[3] World Health Organization. (2022). Global report on diabetes. Retrieved from https://www.who.int/news-room/fact-sheets/detail/diabetes
[4] World Obesity Federation. (2023). Global Obesity Observatory. Retrieved from https://www.worldobesity.org/data/global-obesity-observatory
[5] Pharmaceutical companies' public filings and investor reports for relevant drug portfolios (e.g., Novo Nordisk, Eli Lilly and Company, AstraZeneca). (Various dates).
